Status:
COMPLETED
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency
Lead Sponsor:
Novartis
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-85 years
Phase:
PHASE3
Brief Summary
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and ...
Eligibility Criteria
Inclusion
- History T2DM
- Moderate or Severe Renal Impairment
Exclusion
- Glucose \> 270 mg/dL (\>15 mmol/L)
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
525 Patients enrolled
Trial Details
Trial ID
NCT00646542
Start Date
March 1 2005
Last Update
December 17 2020
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Buenos Aires, Argentina
2
Heidelberg Heights, Australia
3
Winnipeg, Canada
4
Cartago, Costa Rica